Regeneron CEO says the next big thing for biotech isn't AI, it's gene therapy

Regeneron CEO Leonard Schleifer elaborated on the biotech company's latest ventures with CNBC's Jim Cramer on Tuesday and emphasized the importance of genetic research across the industry."The big thing for everybody these days is AI, that's the next big thing. But I don't believe that," Schleifer said. "It's a good tool. But for our business, the really, most important tool, I think, is genetics, it's genes."Schleifer suggested that "associating genes with disease" is going to drive the pharmaceutical indu ...